Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention / 감염과화학요법
Infection and Chemotherapy
; : 686-695, 2021.
Article
in En
| WPRIM
| ID: wpr-914612
Responsible library:
WPRO
ABSTRACT
Current oral antiretroviral agents provide highly effective treatment for patients infected with human immunodeficiency virus (HIV), and can be used as pre-exposure prophylaxis (PrEP) to prevent new HIV infections. Several single-tablet regimens with excellent antiviral efficacy have dramatically improved the quality of life of patients who can adhere to daily oral therapy. However, there is increasing demand on long-acting injectable antiretroviral agents for patients who cannot take oral agents or feel fatigue related to daily pill burden. Monthly long-acting (LA) cabotegravir (CAB) combined with rilpivirine (RPV) has recently been listed as optimizing agent for maintenance of HIV suppression in treatment-experienced patients whose viral load is undetectable for 3 to 6 months. Novel agents with different mechanism of action and long half-life extending dosing interval are being tested in phase 2 and 3 clinical trials. This review summarizes the data of efficacies and safety profiles of LA CAB with RPV regimen, and also new long-acting injectable antiretroviral agents in pipeline.
Full text:
1
Index:
WPRIM
Language:
En
Journal:
Infection and Chemotherapy
Year:
2021
Type:
Article